Market Place
Sourcing Support
Pasithea Therapeutics Announces Positive Data From PAS-004 Trial
26 Sep 2024 //
GLOBENEWSWIRE
Pasithea Therapeutics Announces $5 Million Private Placement
26 Sep 2024 //
GLOBENEWSWIRE
Pasithea Completes PAS-004 Chronic Toxicity Studies
09 Sep 2024 //
GLOBENEWSWIRE
Pasithea Appoints Dr. Rebecca Brown to Scientific Advisory Board
03 Sep 2024 //
GLOBENEWSWIRE
Pasithea Therapeutics To Present At H.C. Wainwright Conference
28 Aug 2024 //
GLOBENEWSWIRE
Pasithea`s Announces Completion of Enrollment PAS-004 in Ongoing Ph1 Trial
13 Jun 2024 //
GLOBENEWSWIRE
Pasithea: Preclinical Data On PAS-004 Inhibiting NRAS Cancer At ASCO 2024
28 May 2024 //
GLOBENEWSWIRE
Pasithea PAS-004 Abstract at ASCO 2024
29 Apr 2024 //
GLOBENEWSWIRE
Pasithea Completes Initial PAS-004 Cancer Trial Dosing
24 Apr 2024 //
GLOBENEWSWIRE
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004
08 Jan 2024 //
GLOBENEWSWIRE
Pasithea Announces Adjournment of Reconvened Meeting of Stockholders
28 Dec 2023 //
GLOBENEWSWIRE
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
19 Dec 2023 //
GLOBENEWSWIRE
Pasithea Announces Positive In Vivo Preclinical Efficacy Data for PAS-004
11 Dec 2023 //
GLOBENEWSWIRE
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
14 Sep 2023 //
GLOBENEWSWIRE
Pasithea to Participate in H.C. Wainwright 25th Annual Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Pasithea publishes in PNAS showing an increase in ±5 integrin expression in ALS
01 Aug 2023 //
GLOBENEWSWIRE
Pasithea Special Committee Rejects Unsolicited Bid from Lucy Scientific
20 Jul 2023 //
GLOBENEWSWIRE
Pasithea Announces Intention to Commence $4.0M Tender Offer for its Common Stock
20 Jul 2023 //
GLOBENEWSWIRE
Pasithea Confirms Previous Creation of Independent Special Committee of its BOD
30 Jun 2023 //
GLOBENEWSWIRE
Pasithea Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery
06 Jun 2023 //
GLOBENEWSWIRE
Pasithea Abstract Accepted for Poster Presentation at 2023 Conference
01 Jun 2023 //
GLOBENEWSWIRE
Pasithea Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at AAAS
02 Mar 2023 //
GLOBENEWSWIRE
Pasithea Chairman, Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture
23 Feb 2023 //
GLOBENEWSWIRE
Pasithea Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award
16 Feb 2023 //
GLOBENEWSWIRE
Pasithea Signs CMC Development and Manufacturing Agreement
26 Jan 2023 //
CONTRACT PHARMA
Pasithea inks CMC development agreement for production of PAS-004
20 Jan 2023 //
PHARMABIZ
Small-cap CNS outfit inks API deal for preclinical MEK inhibitor
19 Jan 2023 //
ENDPTS
Pasithea Signs CMC Development Agreement for the Production of PAS-004
18 Jan 2023 //
GLOBENEWSWIRE
Majority of Stockholders Support Pasithea Directors at Special Meeting
14 Dec 2022 //
GLOBENEWSWIRE
Pasithea Therapeutics to Present at Annual Meeting of the ASC
06 Dec 2022 //
GLOBENEWSWIRE
Pasithea Therapeutics Postpones Special Meeting until December 9, 2022
28 Nov 2022 //
GLOBENEWSWIRE
Pasithea to Present Tolerizing Vaccine Program Results at Immunotherapy 2022
17 Oct 2022 //
GLOBENEWSWIRE
Investor Group Comments on Pasithea’s Defensive & Acquisition of AlloMek
13 Oct 2022 //
BUSINESSWIRE
Pasithea Therapeutics Acquires AlloMek Therapeutics
12 Oct 2022 //
BIOSPACE
Pasithea Therapeutics to Call Special Meeting of Stockholders
03 Oct 2022 //
GLOBENEWSWIRE
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
28 Sep 2022 //
BUSINESSWIRE
Pasithea Therapeutics Appoints Alfred Novak to its Board of Directors
20 Sep 2022 //
FIRSTWORLDPHARMA
Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J
20 Sep 2022 //
GLOBENEWSWIRE
Pasithea Further Strengthens its Scientific Advisory Board with the Appointment
15 Sep 2022 //
GLOBENEWSWIRE
Pasithea to Present at the H.C. Wainwright Global Investment Conference
09 Sep 2022 //
GLOBENEWSWIRE
Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program
18 Aug 2022 //
GLOBENEWSWIRE
Pasithea Announces Results of Preclinical Study Demonstrating Tolerizing
11 Aug 2022 //
GLOBENEWSWIRE
Pasithea Tx Urges Stockholders to Reject Activist Camac’s Unjustified Campaign
02 Aug 2022 //
GLOBENEWSWIRE
Pasithea Therapeutics Awarded a Drug Development Research Grant
14 Jul 2022 //
GLOBENEWSWIRE
Pasithea Therapeutics to Participate in the H.C. Wainwright Conference
23 Jun 2022 //
GLOBENEWSWIRE
Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
22 Jun 2022 //
GLOBENEWSWIRE
Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022
14 Apr 2022 //
GLOBENEWSWIRE
Pasithea Therapeutics Reports Fourth Quarter and Full Year 2021
30 Mar 2022 //
GLOBENEWSWIRE
Pasithea Tx Announces Plans to Open Three New Clinics in the UK by Mid-2022
24 Feb 2022 //
GLOBENEWSWIRE
Pasithea Tx Strengthens Scientific Advisory Board; Appoints Dr. D. Weinberger
09 Feb 2022 //
GLOBENEWSWIRE
Pasithea Tx Initiates NCE Drug Development Program in Multiple Sclerosis
03 Feb 2022 //
GLOBENEWSWIRE
